LY 517717 is an orally active inhibitor of coagulation factor Xa with antithrombotic activity for the study of venous thromboembolism (VTE).

Nothofagin has antioxidant, and antithrombotic activities, it possesses anti-inflammatory activity by inhibiting hyperpermeability, expression of CAMs, and adhesion and migration of leukocytes, thereby endorsing its usefulness as a therapy for vascular inflammatory diseases.

Linotroban（CL-871502） is a potent selective thromboxane (TXA2) receptor antagonist with antithrombotic activity.

Fidexaban (CI1031) is a novel, potent, selective and orally active factor Xa inhibitor that has demonstrated antithrombotic activity in a variety of assays

Trombodipine (PCA-4230) is a platelet aggregation inhibitor with antithrombotic activity and protection against Listeria monocytogenes.

BMS-986141(UDM-003183) is a selective and potent protease-activated receptor-4 (PAR-4) antagonist with oral activity and an IC50 value of 0.4 nM.BMS-98614 exhibits significant antithrombotic effects.

Saponin C from Liriope muscari can be extracted from Liriope muscari, family Liliaceae, has antithrombotic activity and induces autophagy.

MIPS-21335 is a potent PI3KC2α inhibitor with an IC50 value of 7 nM and additionally exhibits inhibitory activity against PI3KC2β, p110α, p110β, and p110δ with IC50 values of 0.043, 0.140, 0.386, and 0.742 μM, respectively. This compound demonstrates an antithrombotic effect [1].

WAY-639228-A has potential antithrombotic and anticoagulant activity for the study of cerebral thrombosis.

AY 31390 is a phosphodiesterase (PDE) inhibitor with antithrombotic activity.

Potent P2Y12 antagonist (IC50 = 17 nM). Displays antiplatelet and antithrombotic activity in vivo. Orally available. Boldron et al (2014) N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist. J.Med.Chem. 57 7293 PMID:25075638

Ilexoside D has ant-allergic, and anti-coagulant activities, it shows anti-tissue factor activity as well as the antithrombotic activity.

GPVI antagonist 3 (Compound 2) is a potential antagonist that shows promising antiplatelet activity by selectively inhibiting the interaction between the Glycoprotein VI (GPVI) receptor and its ligands. It demonstrates potent inhibitory effects, with IC50 values of 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin, and 51.74 μM for thrombin. GPVI is a major collagen receptor on platelets, making it an ideal target for safe and effective antithrombotic treatment. Therefore, GPVI antagonist 3 holds potential as a novel antiplatelet agent [1].

TRIA-662 (Nicotinamide Chloromethylate) is a niacin metabolite excreted via the urinary system.

Tecarfarin sodium is a novel orally active non-competitive vitamin K epoxide reductase antagonist. Tecarfarin sodium has the antithrombotic activity.

Odiparcil is an orally active beta-d-thioxyloside analog. Odiparcil is an indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II). It also has an antithrombotic activity associated with a reduced risk of adverse bleeding events.

Frunexian (EP-7041) is a selective and potent inhibitor of coagulation factor XI/activated factor XI, specifically targeting XIa. It demonstrates antithrombotic activity without associated bleeding risk in a rat mesenteric arterial puncture model and is applicable in extracorporeal membrane oxygenation (ECMO) research [1].

RWJ-445167 is a thrombin and factor Xa dual inhibitor(Ki of 4.0 nM and 230 nM, respectively), with potent antithrombotic activity.

Razaxaban hydrochloride is a highly potent, selective and orally active inhibitor of factor Xa(Ki of 0.19 nM),has strongly antithrombotic activity.

Nafazatrom is a pyrazolinone derivative and lipoxygenase inhibitor that increases endogenous prostacyclin (PGI2) and has experimental anticancer activity. Nafazatrom is also an antithrombotic drug that increases prostacyclin levels and reduces the inciden

Dermatan sulphate sodium, a glycosaminoglycan and thrombin inactivator, exhibits antithrombotic activity by selectively catalyzing the inactivation of thrombin via heparin cofactor II, without interaction with antithrombin III. This compound is noted for its high bioavailability and ability to reduce Bleomycin-induced pulmonary fibrosis damage [1] [2].

Viquidil hydrochloride (Quinotoxine hydrochloride) is an isomer of Quinidine. Viquidil hydrochloride is an agent of cerebral vasodilator with antithrombotic activity.

FXIa-6f is a high affinity, orally bioavailable macrocyclic FXIa inhibitor with antithrombotic activity in preclinical species

Thrombin Inhibitor 2 is a small molecule direct thrombin inhibitor. Thrombin Inhibitor 2 has antithrombotic activity.

Iliparcil is an antithrombotic compound with oral activity.

Fondaparinux sodium (SR-90107A) is an antithrombin-dependent factor Xa inhibitor with antithrombotic activity.

Tecarfarin (ATI-5923) is an orally active and potent vitamin K epoxide reductase (VKOR) antagonist and cannabinoid-1 receptor inverse agonist with antithrombotic activity that attenuates abdominal pain and increases intestinal transit in mice.